Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that RxSight overstated the demand for its products, which contributed to the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of the poor financial results led to a nearly 38% drop in the price of RxSight stock [5].

NEW YORK, Aug. 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of RxSight, Inc. (NASDAQ: RXST). Shareholders who purchased shares of RXST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. DEADLINE: September 22, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesc ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit, titled Makaveev v. RxSight, Inc., et al., is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors, leading to a significant stock price decline [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, resulting in a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, led to another 38% decline in stock price, dropping from $12.79 to $7.95 per share [6].

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. due to alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the defendants overstated the demand for RxSight's products [2]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 as a result of these issues [2]. - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, and the lead plaintiff deadline is September 22, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Case Allegations - The lawsuit alleges that RxSight made false and misleading statements regarding its business, including issues with sales and utilization, overstated demand for its products, and an inability to meet financial guidance for fiscal year 2025 [4]. - The claims suggest that the positive statements made by RxSight about its operations were materially misleading and lacked a reasonable basis [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3].

CONTACT: CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, defendants' positive statements about the Company' ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant decline in stock price, dropping approximately 38% from $26.12 to $16.21 per share on April 3, 2025, after cutting its 2025 revenue forecast due to a market softening noted in the second half of 2024 [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 per share on July 9, 2025 [6].

Core Points - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding a class action lawsuit for shareholders who purchased shares during the specified class period [1] - The class period is defined as November 7, 2024, to July 8, 2025, during which the company allegedly made materially false and misleading statements about its business performance [3] - Allegations include that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization, overstated demand for its products, and an inability to meet previously issued financial guidance for fiscal year 2025 [3] Shareholder Information - Shareholders are encouraged to register for the class action by the deadline of September 22, 2025, to potentially become lead plaintiffs [4] - Registration allows shareholders to receive updates through a portfolio monitoring software regarding the status of the case [4] - Participation in the case incurs no cost or obligation for shareholders [4] Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5]

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified Class Period [1][2]. Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery [2]. Legal Allegations - The lawsuit alleges that RxSight failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the decline to adoption challenges [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

SAN DIEGO, Aug. 4, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges RxSight and certain of RxSight's top executives with violations of the Securities Exchange Act of 1934.If you suffered substantial losses and wish to serve as lead plaintiff of the RxSight class action lawsuit, please provid ...